In a Chinese phase II trial in 107 patients with metastatic HER2-positive (IHC 2+/3+ or FISH+) urothelial carcinoma, this ADC achieved an objective response in 50.5% of patients (95% CI 40.6–60.3%) [13]. This evidence concerns the gene ERBB2 and urothelial carcinoma.